Comparison of the difference in the number of oocytes obtained by administering the ovarian stimulation treatment as usually with administering it only once and later.

Conventional ovarian stimulation vs. stimulation with single injection of Corifollitropin alfa in oocyte donors. Randomized clinical trial. Tail Studio - TAIL study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2019-001343-44-ES

Enrollment

180

Registered

2019-04-30

Start date

2019-05-21

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oocyte donation

Interventions

Trade Name: Elonva Pharmaceutical Form: Injection INN or Proposed INN: CORIFOLLITROPIN ALFA CAS Number: 195962-23-3 Current Sponsor code: Org 36286 Concentration unit: µg microgram(s) Concentration ty

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. To be considered fit to enter the Bernabeu Institute oocyte donation program (Annex I) 2. Age between 18 and 32 years 3. BMI> 18 and 12 (adding both ovaries) 5. Presence of both ovaries 6. Ability to participate and comply with the study protocol 7. Having given written consent 8. Not having received treatment with ovulation stimulators in the 3 months prior to the start of the stimulation. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 180 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Diagnosis of endometriosis at any stage 2. AFC> 20 3. SOP 4. Concurrent participation in another study

Design outcomes

Secondary

Measure	Time frame
Secondary end point(s): • Number of Cumulus-Ovocyte Complex obtained • Duration of stimulation (days) • Total cost of treatment • Cost of oocyte treatment collected in metaphase stage II;Timepoint(s) of evaluation of this end point: At the end of the patient study	—

Primary

Measure	Time frame
Main Objective: To study the efficiency of the use of a single injection of CFA for ovarian stimulation, initiating administration late and without further contribution of FSH activity after the 7th day of stimulation compared to conventional EOC using CFA (administration of the drug 5 days after cesar hormonal contraceptive and supplementation with FSH daily administration from the 8th day of stimulation).;Secondary Objective: • Evaluate the duration of the treatment of the different protocols • Evaluate the total cost of treatment • Evaluate the economic cost by number of oocyte obtained.;Primary end point(s): Number of oocytes;Timepoint(s) of evaluation of this end point: At the end of the patient study	—

Measure

Time frame

Main Objective: To study the efficiency of the use of a single injection of CFA for ovarian stimulation, initiating administration late and without further contribution of FSH activity after the 7th day of stimulation compared to conventional EOC using CFA (administration of the drug 5 days after cesar hormonal contraceptive and supplementation with FSH daily administration from the 8th day of stimulation).;Secondary Objective: • Evaluate the duration of the treatment of the different protocols • Evaluate the total cost of treatment • Evaluate the economic cost by number of oocyte obtained.;Primary end point(s): Number of oocytes;Timepoint(s) of evaluation of this end point: At the end of the patient study

—

Countries

Spain

Contacts

Public ContactAnna Pitas

Instituto Bernabeu

apitas@institutobernabeu.com34965154000

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026